Sanofi has entered the radiopharmaceutical space by licensing AlphaMedix, a therapy developed by partners RadioMedix and Orano Med for the treatment of gastrointestinal cancer. Sanofi is paying €100 million upfront with potential milestone payments of up to €220 million, plus royalties. AlphaMedix targets neuroendocrine tumors, showing promising results in Phase 2 testing with a durable response rate of 62.5%. Sanofi is responsible for global commercialization, with discussions underway with the FDA for regulatory submission. Other big pharma companies, such as Novartis and Bristol Myers Squibb, are also developing radiopharmaceuticals for rare cancers. The radiopharmaceutical market is seeing increased interest and investment from major pharmaceutical companies.
Source link
Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug
